Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abdullah Tolaymat

Neurology Dyer, IN Medical Doctor

NPI 1295022515 CMS profile 9315939

2111 Northwinds Dr, Dyer, IN 46311

Open in the dashboard

General payments

$4,957

239 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abdullah Tolaymat of Dyer, IN is reported in the CMS Open Payments database as having received $4,957 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,032 54
2024 General $1,133 61
2023 General $905 49
2022 General $1,515 58
2021 General $372 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abdullah Tolaymat
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Abdullah Tolaymat were reported at $1,032. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Abdullah Tolaymat Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $372 $438 $104–$2,547 $132
2022 $1,515 $442 $103–$2,388 $149
2023 $905 $464 $119–$2,312 $160
2024 $1,133 $468 $119–$2,323 $164
2025 $1,032 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LivaNova USA, Inc. $836 21 payments
  2. Catalyst Pharmaceuticals, Inc. $790 35 payments
  3. UCB, Inc. $708 48 payments
  4. Neurelis, Inc. $559 26 payments
  5. Jazz Pharmaceuticals Inc. $431 21 payments
  6. Corium, Inc. $389 28 payments
  7. Biocodex, Inc. $209 8 payments
  8. Eisai Inc. $207 11 payments
  9. Tris Pharma Inc $141 8 payments
  10. GRT US Holding, Inc. $107 1 payment
  11. Other $579 32 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,920 236 payments
  2. Education $36 3 payments
Products named General payments · program years 2021–2025
  1. FYCOMPA Neurology $790 35 payments
  2. VALTOCO $559 26 payments
  3. Epidiolex $444 21 payments
  4. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $406 16 payments
  5. Azstarys $389 28 payments
  6. Briviact $304 26 payments
  7. VNS Therapy $285 1 payment
  8. Fintepla $235 13 payments
  9. DIACOMIT $209 8 payments
  10. Fycompa Neurology $207 11 payments
  11. Other $1,049 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record